Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
AssigneeAvMax, Inc.
InventorsVincent J. Wacher, Leslie Z. Benet
Life of this patent
Estimating the term…
Abstract
A method for increasing bioavailability of an orally administered pharmaceutical compound comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with propyl gallate. Improved formulations of pharmaceutical compounds include propyl gallate to enhance the bioavailability of the active ingredient of the pharmaceutical compound.
Claims23
A method for increasing bioavailability of an orally administered pharmaceutical compound, which comprises:
- orally coadministering (1) the pharmaceutical compound to a mammal in need of treatment with the compound and (2) propyl gallate in an amount of the propyl gallate sufficient to provide bioavailability of the compound in the presence of the propyl gallate greater than bioavailability of the compound in the absence of the propyl gallate, the amount being at least 1% by weight relative to the total weight of a mixture including (1) and (2).
A method of formulating an oral pharmaceutical composition, which comprises:
- admixing a pharmaceutical compound, a pharmaceutical carrier, and propyl gallate, the propyl gallate being present in sufficient amount to provide bioavailability of the pharmaceutical compound in the presence of the propyl gallate greater than the bioavailability of the pharmaceutical compound in the absence of the propyl gallate when the pharmaceutical composition is administered orally to a mammal, wherein the propyl gallate is present in an amount sufficient to provide at least 1% by weight propyl gallate relative to the total weight of the pharmaceutical composition.
A method of increasing bioavailability of the active compound of an existing oral pharmaceutical composition, which comprises:
- reformulating the existing composition to provide a reformulated oral composition by admixing the active compound with propyl gallate, the propyl gallate being present in sufficient amount to provide bioavailability of the active compound when administered in the reformulated composition greater than said bioavailability of the active compound when administered in the existing pharmaceutical composition, wherein the propyl gallate is present is an amount sufficient to provide at least 1% by weight propyl gallate relative to the total weight of the reformulated oral composition.
Dependencies are inferred from the claim text.